Understanding CUSE
CUSE is an AI-assisted web tool built on the
Complexity–Uncertainty–Subjectivity–Emotion framework.
It combines innovation, neuroscience, and evidence-based medicine to enhance — rather than replace — human judgment in liver cancer care.
By structuring information and highlighting the most relevant evidence, CUSE helps clinicians analyze complexity, manage uncertainty, and make informed, patient-centered decisions.
In short, CUSE becomes and innovatin tool that amplifies expertise — turning data into knowledge, and knowledge into confident, evidence-driven care.

The value of CUSE
Guiding clinical decisions through evidence and patient-centered care.
CUSE unites clinical expertise and artificial intelligence to interpret each patient’s situation with precision and empathy, supporting decisions based on science and guided by more personalized, balanced, and patient-centered priorities.

Explore the clinical scenario
Through the BCLC staging system, get treatment recommendations, contextualized to real-world complexity and aligned with patient-defined priorities.

Structured and guided reasoning
Receive structured, evidence-based guidance throughout your decision-making process from case definition to the scientific evidence needed for multidisciplinary discussion.
Sign up for updates
Stay informed about CUSE’s development
Be among the first to hear about our upcoming global launch.
Fields with an asterisk (*) are required.
Current collaborators
Institutional Partners
CUSE is a digital health platform, currrently under development, driven by the Fundació Privada Món Clínic Barcelona and with the institutional support of Clínic Barcelona.


Development Support
CUSE is being developed in collaboration with several technology and innovation partners:
Hiberus, Lighthouse DIG, Global Liver Institute and Captug




Current Sponsors:

Gold

Silver

Bronze
If you are interested in exploring collaboration opportunities please contact us at cuse@fundaciomonclinicbarcelona.cat
CUSE © Fundació Privada Món Clínic Barcelona 2025




